Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers November 18, 2017
Pharmacy Choice - Pharmaceutical News - EyeGate Pharmaceuticals - November 18, 2017

Pharmacy News Article

 7/16/17 - EyeGate Pharmaceuticals

EyeGate Pharmaceuticals


EyeGate Pharma is developing a proprietary platform of medicines to treat diseases of the eye using its unique, non-invasive, iontophoretic drug-delivery system called EyeGate II. This proprietary technology platform is based on over 10-years of development at the Bascom Palmer Eye Institute at the University of Miami and has been tested extensively in both preclinical and human studies in Europe. Because of the human eye's special anatomy, effective delivery of medicines to treat chronic disease or diseases in the mid and posterior segments of the eye is less than adequate. They believe the EyeGate II Delivery System will offer both physicians and patients an important new alternative in advancing the treatment of eye disease.



Prior Year Revenue Current Year Revenue Next Year Revenue
Sign up as Investor Sign up as Investor Sign up as Investor
Company Age Employees Sub-Industry
19 years, 6 months 7 Other Biotechnology
Company Type Stock Exchange Stock Symbol
Privately-Held - -



Thomas Hancock

Thomas E. Hancock Tom has nearly 20 years of venture capital experience and securities analyst experience. 

He currently represents Nexus on the Boards of Presidio Pharmaceuticals, SpectraAnalysis, EyeGate Pharmaceuticals, MyoScience and Magellan Biosciences. Over the last several years, Tom has led investments in numerous successful private companies, including Panacos Pharmaceuticals and Atricure. 

Prior to joining Nexus, Tom was a Managing Director and Senior Equity Analyst at U. S. Bancorp Piper Jaffray covering publicly traded biopharmaceutical companies and drug discovery supplier companies. While at Piper, he published research notes, reports, industry overviews and technology updates for the benefit of the investment community on Gilead Sciences, Tularik, Human Genome Sciences, Millennium Pharmaceuticals, Applied Biosystems, Charles River Laboratories, Invitrogen and Millipore, among others.

Paul Chaney


Morton Goldberg


Praveen Tyle


Alain Maiore


Michael Mullen


J. Cleftie

© Copyright iCrowdNewswire LLC 2017.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Last Chance
Nov 19: Biosimilar Drugs: Legal, Regulatory & Safety Considerations
Nov 20: Obesity Management: Overview of Pharmacotherapy
Nov 21: Standards of Practice for Filling Controlled Substance Prescriptions in Florida
Nov 22: Medical Marijuana: Examining the Science, Not the Politics
Nov 27: Drug Diversion and the Law: Updates and Considerations
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement